Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.

Slides:



Advertisements
Similar presentations
K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory.
Advertisements

HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part D2 – AD brain scans – metabolism - PET NUCLEAR MEDICINE.
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.
Department of Neurology, Mayo Clinic Arizona
December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.
TESTING A LEPTIN PRODUCT AS A NOVEL THERAPY FOR ALZHEIMER’S DISEASE
DIAN Treatment Trials An Update Sunday February 10, :00 to 6:00 PM CST Presented by Randall Bateman MD DIAN Therapeutic Trials Unit Director DIAN.
©2011 MFMER | slide-1 Alzheimer Disease: Update Neill R. Graff-Radford, MBBCh, FRCP Professor of Neurology Mayo College of Medicine.
Alzheimer’s Disease Neuroimaging Initiative Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Householder, MS.
Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.
Alzheimer's Disease – Current Status; Future Perspectives
Pr Bruno Dubois Head of the Dementia Research Center (IMMA)
Alzheimer’s Disease and Biomarkers John H. Dougherty,Jr.M.D. Medical Director Cole Neuroscience Center.
EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.
How To Improve Memory Performance and Keep Your Brain Young Gary W. Small, MD Parlow-Solomon Professor on Aging Professor of Psychiatry & Biobehavioral.
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.
ALZHEIMER PATHOLOGY AND NEUROPLASTICITY AD ATTACKS NEUROPLASTIC MECHANISMS NEUROPLASTICITY AS THE FOCUS OF THE ALZHEMIER ATTACK ALZHEIMER ATTACK AS A MODEL.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Disclosure of research results: should policies be changed? Melanie B. Shulman, M.D., M.Phil. Clinical Associate Professor of Neurology and Psychiatry.
MRI as a Potential Surrogate Marker in the ADCS MCI Trial
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.
Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.
Update Arg-ADNI Instituto de Investigaciones Neurológicas (FLENI)
PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
Kimiko Domoto-Reilly, MD Cognitive / Behavioral Neurology Fellow Massachusetts General Hospital & Brigham and Women’s Hospital.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Update and Thank you to participants Bradley Hyman MD PhD Director, Mass ADRC ViceChair, Neurology, Massachusetts General Hospital.
Structural and Functional Neuroimaging in the Diagnosis of Dementia John M. Ringman, M.D. Assistant Professor UCLA Department of Neurology.
Alzheimer’s Disease: 진단과 치료
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Mechanism of Amyloid Removal in Patients With Alzheimer.
CASES SERIES BRAIN FDG PET SCAN IN DEMENTIA PATIENTS
Arg-ADNI Gustavo E. Sevlever (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, Ricardo F. Allegri and Arg-ADNI group. Memory and Aging Center.
DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)
Update of China-ADNI Kuncheng Li, MD. PhD.
ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue
José L Molinuevo, Craig Ritchie, Miia Kivipelto
INDIA - ADNI Dr Naren Rao
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Rosa Maria Moresco University of Milan Bicocca
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
Update of China-ADNI Kuncheng Li, MD. PhD.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Presenter: Dr. Patricio Chrem
Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar
Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;
Table 2. Data Sharing for (Reporting Period)
Volume 2, Issue 1, Pages (January 2016)
Imaging AD Progression Amyloid Imaging Agents.
INDIA - ADNI Dr Naren Rao
ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue
Blood-Based Biomarkers in the QC Program?
José L Molinuevo, Craig Ritchie, Miia Kivipelto
Update of China-ADNI Kuncheng Li, MD. PhD.
ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue
AAIC 2018 Biomarker Rates of Change in Autosomal Dominant Versus “Sporadic” Alzheimer Disease John C. Morris, MD On behalf of MW Weiner, L Beckett, T.
Presenter: Dr. Patricio Chrem
Update of China-ADNI Kuncheng Li, MD. PhD.
Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)
Argentina Arg-ADNI Ezequiel Surace, PhD.
Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.
Figure 2 Aβ-PET scans obtained using different tracers
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Presentation transcript:

Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and Aging Center Institute for Neurological Research Buenos Aires, Argentina Washington D.C., July 17, 2015 *speaker

Institute for Neurological Research Institute for Neurological Rehabilitation Center for Molecular Imaging Memory and Aging Center Institute for Neurological Research FLENI Buenos Aires Argentina

Update arg-ADNI Preliminary Results Future Tasks Update of Argentine ADNI

(*) Stream Chair Management Committee Allegri RF, Sevlever G, Guinjoan S, Gustafson D, Vazquez S. Clinical Stream Cognitive Neurologists Ricardo F. Allegri (*) Patricio Chrem Mendez Maria Julieta Russo Jorge CamposPsychiatrists Salvador GuinjoanNeuropsychologists María Eugenia Martín Florencia Clarens Paula Harris Neuroimaging Stream Silvia Vazquez S (*) Esteban Obenaus German Falasco Leandro Urrutia Fernando Ventrice Laboratory Stream Gustavo Sevlever (*) Horacio Martinetto Ezequiel Surace Miguel Riudavetz Epidemiological Stream Deb Gustafson (*) Study Coordinator Patricio Chrem Mendez Secretary Noelia Egido Data Entry Federico Nahas Study Coordinator Patricio Chrem Mendez Secretary Noelia Egido Data Entry Federico Nahas Arg-ADNI Staff

First patient / first visit Q Last patient / last visit Q First Year 2013 / 2014 Arg-ADNI Study Timeline Month / 2015 Month / 2016 B B 1 1 B B 2,5 4 year

Arg-ADNI Patients’ Flowchart Patients Screened at FLENI Nº= 60 Early MCI Nº=12 Healthy Controls Nº= 15 Late MCI Nº= 16 Dementia AD Nº=13 Screening Failure Nº= 7 Patients Screened to ADNI Nº= Claustrophobia 1 Psychiatric Disease 1 Cancer 1 Adult ADHD 2 without informant Patients Followed (Baseline) Nº= 56 Dropout Nº= 3 2 removed inform.cons 1 by distance/caregiver Early MCI Nº=10 Healthy Controls Nº= 13 Late MCI Nº= 16 Dementia AD Nº=12 Early MCI Nº=? Healthy Controls Nº= ? Late MCI Nº= ? Dementia AD Nº=? Patients Followed Month 12 Nº= 51 Patients Followed Month 48 Nº= ? New Patients Invited to ADNI Nº= 6 Early MCI Nº=1/10 Healthy Controls Nº= 7/13 Late MCI Nº= 7/16 Dementia AD Nº=4/12 Patients Followed Month 30 Nº= 19/51 Dropout Nº= 5 2 removed inform.cons 2 Cancer 1 Institutionalized

12 30 months months Normal Control (nº=13) did not progress Early MCI (nº=10)1 progressed (10%) Late MCI (nº=16)4 progressed (25%) Arg-ADNI Follow up Rate of Progression

Screening / Baseline % compl. Month 12 Month 30 Month 48 Demographic data(+) 100% (+) Clinical, NPS, NPSq(+) 100% (+) Cognitive Reserve (MCI)(+) MCI Blood(+) APOE(+) 100% CSF AB42/Tau(+) 71% (+) MRI (3T)(+) 100% (+) FDG PET Scan(+) 100% (+) PiB PET scan(+) 91% (+) Tau PET scan (AVID) (+) Arg-ADNI Schedule of evaluations.

Update arg-ADNI Preliminary Results Future Tasks Update of Argentine ADNI

Brain 18 FDG PET scan Uptake Map Hypometabolism Map Brain 11 C-PiB PET scan Healthy AD

Arg-ADNI 11 C – PIB - PET imaging

Arg-ADNI Cognitive Reserve and Aβ-42 (CSF) in MCI patients Paula Harris, Marcos Fernandez Suarez, Ezequiel Surace. et al., 2015 (in press in Neurospcyhiatric Disease and Treatment) Group 1 (Cut off < 532,5) Group 2 (Cut off  532,5) p Nº Age70,5 (8,4)65,6 (7,9)ns Education12,9 (4,3)14,5 (3,8)ns MMSE28,5 (1,5)28,5 (0,8)ns CRQ13,3 (5,5)17,2 (2,9) p <0,05 TAP-BA37 (9,9)42,69 (6,2)ns CSF  Aβ ,0 (87,0)959,0 (251,0) <0,001  TAU-T 501,3 (260,8)200,6 (85,5)<0,001  P-TAU 75,2 (45,8)38,9 (16,2) <0,05  Alz-profile2,6 (7,8)2,0 (0,6)ns Correlation between Cognitive Reserve Questionnaire and A  1-42 level CRQ: Cognitive Reserve Questionnaire (Rami et al., 2011)

Arg-ADNI Free Recall and Recognition in MCI patients with amyloid (+) vs amyloid (-) MFlorencia Clarens, María E Martin; Fernanda. Tapajoz et al., 2015 Amyloid (-) Amyloid (+) p Nº1112 Age71.7 (6.7)72.6 (6.3)ns Education13.9 (3.8)12.5 (3.9)ns MMSE28.6 (1.1)27.5 (2.5)ns NPI33.3 (12.2)30.8 (12.5)ns Test Result Variable(s)Area Std. Error(a) Asymptotic Sig.(b) RAVLT total,667,121, Minute Delay Total,767,111,035 Recognition Score,838,086,008 hipocampo izq,525,128,843 hipocampo der,550,127,692 Demographic data

Arg-ADNI FLENI Brain Bank

Update arg-ADNI Preliminary Results Future Tasks Update of Argentine ADNI

Tau tracer (PETscan) in ADNI Cohort AVID (AV 1451) Start-up: April 2016 Future Tasks Month 48 (+) ADNI cohort (51ptes) Demographic data Clinical, NPS, NPSq Cognitive Reserve (MCI) Blood APOE CSF AB42/Tau MRI (3T) FDG PET Scan PiB PET scan Tau PET scan (AVID)

Arg-DIAN (Dominantly Inherited Alzheimer Network) National grant application (CONICET) to study an Argentine DIAN cohort of 40 participant. Start-up: August, 2015 (Prof. J.Morris / Buenos Aires) Future Tasks

AD Biomarkers in Down Syndrome PI: Dr. Ezequiel Surace National grant application (CONICET) April 2015 to study an Argentine cohort of 10 participant. Start-up May 2016 Future Tasks

Memory and Aging Center

Update Arg-ADNI Memory and Aging Center Institute for Neurological Research Buenos Aires, Argentina Washington D.C., July 17, 2015